Alzheimer's disease drug development pipeline: 2020.

ABSTRACT:

Introduction

Alzheimer's disease (AD) is a growing public health concern affecting millions of patients worldwide and costing billions of dollars annually. We review the pipeline of drugs and biologics in clinical trials for the treatment of AD. We use the Common Alzheimer's and Related Dementias Research Ontology (CADRO) to classify treatment targets and mechanisms of action. We review our annual pipeline reports for the past 5 years to provide longitudinal insight into clinical trials and drug development for AD.

Methods

We reviewed ClinicalTrials.gov as of February 27, 2020, and identified all trials of pharmacologic agents currently being developed for treatment of AD as represented on this widely used U.S. Food and Drug Administration registry.

Results

There are

SUBMITTER: Cummings J 

PROVIDER: S-EPMC7364858 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature